

Resource Summary Report

Generated by PRECISE-TBI on Sep 7, 2026

University of Colorado Anschutz Medical Campus Cancer Center Cell Technologies Shared Resource Core Facility

RRID:SCR_021982

Type: Tool

Proper Citation

University of Colorado Anschutz Medical Campus Cancer Center Cell Technologies
Shared Resource Core Facility (RRID:SCR_021982)

Resource Information

URL: <https://medschool.cuanschutz.edu/colorado-cancer-center/research/shared-resources/cell-technologies>

Proper Citation: University of Colorado Anschutz Medical Campus Cancer Center Cell Technologies Shared Resource Core Facility (RRID:SCR_021982)

Description: Supports basic and translational research projects in biomedical research. CTSR produces hybridomas/monoclonal antibodies to enhance basic research and preclinical studies and makes recombinant proteins for mechanistic and structural studies on proteins. Provides multiple platforms and analytic modules for real time live-cell imaging of cultured cells and organoids to enhance analysis of cancer cell biology. In addition, we maintain a collection of authenticated human cell lines for use in biomedical research. Sign in to iLab using University of Colorado credentials.

Abbreviations: CTSR

Synonyms: Cell Technologies Shared Resource

Resource Type: access service resource, core facility, service resource

Keywords: ABRF, USEdit

Resource Name: University of Colorado Anschutz Medical Campus Cancer Center Cell Technologies Shared Resource Core Facility

Resource ID: SCR_021982

Alternate IDs: ABRF_1307

Alternate URLs: <https://coremarketplace.org/?FacilityID=1307>

Record Creation Time: 20220421T050138+0000

Record Last Update: 20260905T133423+0000

Ratings and Alerts

No rating or validation information has been found for University of Colorado Anschutz Medical Campus Cancer Center Cell Technologies Shared Resource Core Facility.

No alerts have been found for University of Colorado Anschutz Medical Campus Cancer Center Cell Technologies Shared Resource Core Facility.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 21 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#).

Doss RM, et al. (2026) Exon-skipping due to bi-allelic splice site mutations in the neurodevelopmental disease gene LNPK. HGG advances, 7(1), 100543.

Christenson JL, et al. (2026) Metastasis-Associated Wound Repair Promotes Reciprocal Lung Epithelium Activation and Breast Cancer Metastatic Outgrowth. Cancer research communications, 6(4), 750.

Sottnik JL, et al. (2026) Advanced models of lobular breast cancer metastasis capture clinical organ tropism, endocrine response, and bone remodeling. bioRxiv : the preprint server for biology.

Garcia C, et al. (2026) FATP2-mediated lipid metabolism enhances chimeric antigen receptor T-cell therapy resistance in B-cell acute lymphoblastic leukemia. Leukemia, 40(8), 1763.

Sottnik JL, et al. (2026) Altered MDC1 Interactions and Dysfunctional DNA Repair in Lobular Breast Cancer Confers Sensitivity to PARP Inhibition. Cancer research, 86(7), 1605.

Alvarez-Eraso KLF, et al. (2026) Estradiol Reprograms Microglia to Create an Immune-Suppressed Niche Permissive to Breast Cancer Brain Metastasis. bioRxiv : the preprint server for biology.

Fox MS, et al. (2026) Brain FGF2 and NCAM1 contribute to FGFR1-dependent progression of estrogen receptor-positive breast cancer brain metastases. Nature communications, 17(1).

Musick M, et al. (2025) CDH1 loss remodels gene expression and lineage identity in human mammary epithelial cells. *bioRxiv : the preprint server for biology*.

Purdy SC, et al. (2025) eIF3d and eIF3e mediate selective translational control of hypoxia that can be inhibited by small molecules. *Cell reports*, 44(12), 116643.

Rosenbaum SR, et al. (2025) EYA3 regulation of NF- κ B and CCL2 suppresses cytotoxic NK cells in the premetastatic niche to promote TNBC metastasis. *Science advances*, 11(19), eadt0504.

Purdy SC, et al. (2025) eIF3d and eIF3e mediate selective translational control of hypoxia that can be inhibited by novel small molecules. *bioRxiv : the preprint server for biology*.

Elder AM, et al. (2025) Semaphorin7A and PD-L1 cooperatively drive immunosuppression during mammary involution and breast cancer. *Cell reports*, 44(5), 115676.

Zielinski JM, et al. (2025) Thyroid Hormone Receptor α Suppresses Cancer Cell Activity by Differential Regulation of Glycogen Metabolism. *Endocrinology*, 166(12).

Woodruff ER, et al. (2025) Ablation of hematopoietic stem cell derived adipocytes reduces tumor burden in syngeneic mouse models of high-grade serous carcinoma. *bioRxiv : the preprint server for biology*.

Coleman H, et al. (2024) Effect of mechanical stresses on viral capsid disruption during droplet formation and drying. *Colloids and surfaces. B, Biointerfaces*, 233, 113661.

Sottnik JL, et al. (2024) Co-regulator activity of Mediator of DNA Damage Checkpoint 1 (MDC1) is associated with DNA repair dysfunction and PARP inhibitor sensitivity in lobular carcinoma of the breast. *bioRxiv : the preprint server for biology*.

Persenaire C, et al. (2024) VDX-111, a novel small molecule, induces necroptosis to inhibit ovarian cancer progression. *Molecular carcinogenesis*, 63(7), 1248.

Rosenbaum SR, et al. (2024) An EYA3/NF- κ B/CCL2 signaling axis suppresses cytotoxic NK cells in the pre-metastatic niche to promote triple negative breast cancer metastasis. *bioRxiv : the preprint server for biology*.

Hughes CJ, et al. (2023) SIX1 and EWS/FLI1 co-regulate an anti-metastatic gene network in Ewing Sarcoma. *Nature communications*, 14(1), 4357.

Yang Z, et al. (2023) HIF-1 α drives resistance to ferroptosis in solid tumors by promoting lactate production and activating SLC1A1. *Cell reports*, 42(8), 112945.